

Guillermo Ruiz-Irastorza

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1335296/publications.pdf>

Version: 2024-02-01

239
papers

22,490
citations

20815

60
h-index

9342

143
g-index

265
all docs

265
docs citations

265
times ranked

15623
citing authors

#	ARTICLE	IF	CITATIONS
1	Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2012, 64, 2677-2686.	6.7	3,838
2	2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus. <i>Arthritis and Rheumatology</i> , 2019, 71, 1400-1412.	5.6	1,098
3	Antiphospholipid syndrome. <i>Lancet, The</i> , 2010, 376, 1498-1509.	13.7	916
4	Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 20-28.	0.9	817
5	Systemic lupus erythematosus. <i>Nature Reviews Disease Primers</i> , 2016, 2, 16039.	30.5	816
6	The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 795-810.	0.9	780
7	2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1151-1159.	0.9	759
8	EULAR recommendations for the management of antiphospholipid syndrome in adults. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1296-1304.	0.9	664
9	Anti-inflammatory and immunosuppressive drugs and reproduction. <i>Arthritis Research and Therapy</i> , 2006, 8, 209.	3.5	469
10	Evidence-based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody-positive patients: Report of a Task Force at the 13th International Congress on Antiphospholipid Antibodies. <i>Lupus</i> , 2011, 20, 206-218.	1.6	467
11	Vitamin D deficiency in systemic lupus erythematosus: prevalence, predictors and clinical consequences. <i>Rheumatology</i> , 2008, 47, 920-923.	1.9	396
12	Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1706-1713.	0.9	391
13	The frequency and outcome of lupus nephritis: results from an international inception cohort study. <i>Rheumatology</i> , 2016, 55, 252-262.	1.9	370
14	Morbidity and Mortality in Systemic Lupus Erythematosus During a 5-Year Period: A Multicenter Prospective Study of 1,000 Patients. <i>Medicine (United States)</i> , 1999, 78, 167-175.	1.0	367
15	Effect of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus. <i>Lupus</i> , 2006, 15, 577-583.	1.6	351
16	INCREASED RATE OF LUPUS FLARE DURING PREGNANCY AND THE PUERPERIUM: A PROSPECTIVE STUDY OF 78 PREGNANCIES. <i>Rheumatology</i> , 1996, 35, 133-138.	1.9	306
17	A systematic review of secondary thromboprophylaxis in patients with antiphospholipid antibodies. <i>Arthritis and Rheumatism</i> , 2007, 57, 1487-1495.	6.7	294
18	Predictors of major infections in systemic lupus erythematosus. <i>Arthritis Research and Therapy</i> , 2009, 11, R109.	3.5	288

#	ARTICLE	IF	CITATIONS
19	Autoimmune diseases induced by biological agents. <i>Autoimmunity Reviews</i> , 2010, 9, 188-193.	5.8	282
20	Infection risk in systemic lupus erythematosus patients: susceptibility factors and preventive strategies. <i>Lupus</i> , 2013, 22, 1286-1294.	1.6	274
21	Systemic lupus erythematosus. <i>Lancet, The</i> , 2001, 357, 1027-1032.	13.7	271
22	Cancer risk in systemic lupus: An updated international multi-centre cohort study. <i>Journal of Autoimmunity</i> , 2013, 42, 130-135.	6.5	249
23	Hepatitis B Virus (HBV) Reactivation in Patients Receiving Tumor Necrosis Factor (TNF)-Targeted Therapy. <i>Medicine (United States)</i> , 2011, 90, 359-371.	1.0	247
24	Antiphospholipid syndrome. <i>Nature Reviews Disease Primers</i> , 2018, 4, 17103.	30.5	233
25	Antiphospholipid syndrome in obstetrics. <i>Best Practice and Research in Clinical Obstetrics and Gynaecology</i> , 2012, 26, 65-76.	2.8	218
26	Efficacy of rituximab in 164 patients with biopsy-proven lupus nephritis: Pooled data from European cohorts. <i>Autoimmunity Reviews</i> , 2012, 11, 357-364.	5.8	209
27	High Impact of Antiphospholipid Syndrome on Irreversible Organ Damage and Survival of Patients With Systemic Lupus Erythematosus. <i>Archives of Internal Medicine</i> , 2004, 164, 77.	3.8	195
28	Glucocorticoid use and abuse in SLE. <i>Rheumatology</i> , 2012, 51, 1145-1153.	1.9	186
29	State of the art: Reproduction and pregnancy in rheumatic diseases. <i>Autoimmunity Reviews</i> , 2015, 14, 376-386.	5.8	169
30	Assessing disease activity in SLE patients during pregnancy. <i>Lupus</i> , 1999, 8, 677-684.	1.6	166
31	Glucocorticoids and irreversible damage in patients with systemic lupus erythematosus. <i>Rheumatology</i> , 2014, 53, 1470-1476.	1.9	166
32	Bleeding and Recurrent Thrombosis in Definite Antiphospholipid Syndrome. <i>Archives of Internal Medicine</i> , 2002, 162, 1164.	3.8	163
33	Seizure disorders in systemic lupus erythematosus results from an international, prospective, inception cohort study. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1502-1509.	0.9	143
34	Biologics-induced autoimmune diseases. <i>Current Opinion in Rheumatology</i> , 2013, 25, 56-64.	4.3	143
35	A Systematic Review of the Off-Label Use of Biological Therapies in Systemic Autoimmune Diseases. <i>Medicine (United States)</i> , 2008, 87, 345-364.	1.0	136
36	Autoantibodies as biomarkers for the prediction of neuropsychiatric events in systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 1726-1732.	0.9	132

#	ARTICLE	IF	CITATIONS
37	Changes in vitamin D levels in patients with systemic lupus erythematosus: Effects on fatigue, disease activity, and damage. <i>Arthritis Care and Research</i> , 2010, 62, 1160-1165.	3.4	121
38	Systemic lupus erythematosus in Europe at the change of the millennium: Lessons from the "Euro-Lupus Project". <i>Autoimmunity Reviews</i> , 2006, 5, 180-186.	5.8	115
39	Lymphoma risk in systemic lupus: effects of disease activity versus treatment. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 138-142.	0.9	115
40	Pregnancy and reproduction in autoimmune rheumatic diseases. <i>Rheumatology</i> , 2011, 50, 657-664.	1.9	112
41	SYSTEMIC LUPUS ERYTHEMATOSUS FLARES DURING PREGNANCY. <i>Rheumatic Disease Clinics of North America</i> , 1997, 23, 15-30.	1.9	107
42	Anti-C1q antibodies in systemic lupus erythematosus. <i>Lupus</i> , 2015, 24, 42-49.	1.6	106
43	Mood Disorders in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. <i>Arthritis and Rheumatology</i> , 2015, 67, 1837-1847.	5.6	98
44	Antimalarials may influence the risk of malignancy in systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2007, 66, 815-817.	0.9	91
45	High risk of tuberculosis in systemic lupus erythematosus?. <i>Lupus</i> , 2006, 15, 232-235.	1.6	88
46	Management of antiphospholipid syndrome. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 155-161.	0.9	85
47	Headache in Systemic Lupus Erythematosus: Results From a Prospective, International Inception Cohort Study. <i>Arthritis and Rheumatism</i> , 2013, 65, 2887-2897.	6.7	84
48	The adjusted global antiphospholipid syndrome score (aGAPSS) and the risk of recurrent thrombosis: Results from the APS ACTION cohort. <i>Seminars in Arthritis and Rheumatism</i> , 2019, 49, 464-468.	3.4	79
49	Clinical associations of the metabolic syndrome in systemic lupus erythematosus: data from an international inception cohort. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1308-1314.	0.9	78
50	Stroke and the antiphospholipid syndrome: consensus meeting Taormina 2002. <i>Lupus</i> , 2003, 12, 508-513.	1.6	71
51	Transiently positive anticardiolipin antibodies and risk of thrombosis in patients with systemic lupus erythematosus. <i>Lupus</i> , 2007, 16, 810-816.	1.6	71
52	Low-dose aspirin vs low-dose aspirin plus low-intensity warfarin in thromboprophylaxis: a prospective, multicentre, randomized, open, controlled trial in patients positive for antiphospholipid antibodies (ALIWAPAS). <i>Rheumatology</i> , 2014, 53, 275-284.	1.9	71
53	Impact of early disease factors on metabolic syndrome in systemic lupus erythematosus: data from an international inception cohort. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1530-1536.	0.9	70
54	Antinuclear Antibody "Negative Systemic Lupus Erythematosus in an International Inception Cohort. <i>Arthritis Care and Research</i> , 2019, 71, 893-902.	3.4	70

#	ARTICLE	IF	CITATIONS
55	Measuring systemic lupus erythematosus activity during pregnancy: Validation of the lupus activity index in pregnancy scale. <i>Arthritis and Rheumatism</i> , 2004, 51, 78-82.	6.7	69
56	Prednisone in lupus nephritis: How much is enough?. <i>Autoimmunity Reviews</i> , 2014, 13, 206-214.	5.8	69
57	Treating systemic lupus erythematosus in the 21st century: new drugs and new perspectives on old drugs. <i>Rheumatology</i> , 2020, 59, v69-v81.	1.9	69
58	Restrictive Use of Oral Glucocorticoids in Systemic Lupus Erythematosus and Prevention of Damage Without Worsening Long-Term Disease Control: An Observational Study. <i>Arthritis Care and Research</i> , 2018, 70, 582-591.	3.4	67
59	Lupus and pregnancy: ten questions and some answers. <i>Lupus</i> , 2008, 17, 416-420.	1.6	66
60	Pulmonary hypertension in systemic lupus erythematosus: prevalence, predictors and diagnostic strategy. <i>Autoimmunity Reviews</i> , 2013, 12, 410-415.	5.8	66
61	The efficacy of hydroxychloroquine in altering pregnancy outcome in women with antiphospholipid antibodies. <i>Thrombosis and Haemostasis</i> , 2016, 115, 285-290.	3.4	66
62	Risk Factors for Esophageal Candidiasis. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2000, 19, 96-100.	2.9	63
63	Hydroxychloroquine: the cornerstone of lupus therapy. <i>Lupus</i> , 2008, 17, 271-273.	1.6	63
64	Antiphospholipid antibodies predict early damage in patients with systemic lupus erythematosus. <i>Lupus</i> , 2004, 13, 900-905.	1.6	60
65	Lupus and pregnancy: integrating clues from the bench and bedside. <i>European Journal of Clinical Investigation</i> , 2011, 41, 672-678.	3.4	60
66	Comparison of high versus low-medium prednisone doses for the treatment of systemic lupus erythematosus patients with high activity at diagnosis. <i>Autoimmunity Reviews</i> , 2015, 14, 875-879.	5.8	57
67	Pulmonary Disorders Induced by Monoclonal Antibodies in Patients with Rheumatologic Autoimmune Diseases. <i>American Journal of Medicine</i> , 2011, 124, 386-394.	1.5	55
68	Cerebrovascular Events in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. <i>Arthritis Care and Research</i> , 2018, 70, 1478-1487.	3.4	55
69	Psychosis in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. <i>Arthritis and Rheumatology</i> , 2019, 71, 281-289.	5.6	55
70	Second week methyl-prednisolone pulses improve prognosis in patients with severe coronavirus disease 2019 pneumonia: An observational comparative study using routine care data. <i>PLoS ONE</i> , 2020, 15, e0239401.	2.5	54
71	Glucocorticoids in Systemic Lupus Erythematosus. Ten Questions and Some Issues. <i>Journal of Clinical Medicine</i> , 2020, 9, 2709.	2.4	54
72	Rates of, and risk factors for, severe infections in patients with systemic autoimmune diseases receiving biological agents off-label. <i>Arthritis Research and Therapy</i> , 2011, 13, R112.	3.5	53

#	ARTICLE	IF	CITATIONS
73	Repeated pulses of methyl-prednisolone with reduced doses of prednisone improve the outcome of class III, IV and V lupus nephritis: An observational comparative study of the Lupus-Cruces and lupus-Bordeaux cohorts. <i>Autoimmunity Reviews</i> , 2017, 16, 826-832.	5.8	53
74	Evaluation of phosphatidylserine-dependent antiprothrombin antibody testing for the diagnosis of antiphospholipid syndrome: results of an international multicentre study. <i>Lupus</i> , 2017, 26, 266-276.	1.6	53
75	Pseudochylothorax: Report of 2 Cases and Review of the Literature. <i>Medicine (United States)</i> , 1999, 78, 200-207.	1.0	52
76	Infection is the major trigger of hemophagocytic syndrome in adult patients treated with biological therapies. <i>Seminars in Arthritis and Rheumatism</i> , 2016, 45, 391-399.	3.4	52
77	The prevalence and determinants of anti-DFS70 autoantibodies in an international inception cohort of systemic lupus erythematosus patients. <i>Lupus</i> , 2017, 26, 1051-1059.	1.6	52
78	Glucocorticoids and antimalarials in systemic lupus erythematosus: an update and future directions. <i>Current Opinion in Rheumatology</i> , 2018, 30, 482-489.	4.3	52
79	Off-label use of rituximab for systemic lupus erythematosus in Europe. <i>Lupus Science and Medicine</i> , 2016, 3, e000163.	2.7	51
80	Multicriteria decision analysis process to develop new classification criteria for systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 634-640.	0.9	51
81	Cardiovascular events prior to or early after diagnosis of systemic lupus erythematosus in the systemic lupus international collaborating clinics cohort. <i>Lupus Science and Medicine</i> , 2016, 3, e000143.	2.7	50
82	Evaluation of systemic lupus erythematosus activity during pregnancy. <i>Lupus</i> , 2004, 13, 679-682.	1.6	49
83	Note of Republication: A Prospective International Study on Adherence to Treatment in 305 Patients With Flaring SLE: Assessment by Drug Levels and Self-Administered Questionnaires. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 103, 1074-1082.	4.7	48
84	Management of Thrombosis in Antiphospholipid Syndrome and Systemic Lupus Erythematosus in Pregnancy. <i>Annals of the New York Academy of Sciences</i> , 2005, 1051, 606-612.	3.8	46
85	Flares after hydroxychloroquine reduction or discontinuation: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 370-378.	0.9	42
86	Antiaggregant and anticoagulant therapy in systemic lupus erythematosus and Hughes' syndrome. <i>Lupus</i> , 2001, 10, 241-245.	1.6	40
87	A Longitudinal Analysis of Outcomes of Lupus Nephritis in an International Inception Cohort Using a Multistate Model Approach. <i>Arthritis and Rheumatology</i> , 2016, 68, 1932-1944.	5.6	40
88	Neuropsychiatric events in systemic lupus erythematosus: a longitudinal analysis of outcomes in an international inception cohort using a multistate model approach. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 356-362.	0.9	40
89	Peripheral Nervous System Disease in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. <i>Arthritis and Rheumatology</i> , 2020, 72, 67-77.	5.6	39
90	High intensity anticoagulation in the prevention of the recurrence of arterial thrombosis in antiphospholipid syndrome: â€˜PROSâ€™™ and â€˜CONSâ€™™. <i>Autoimmunity Reviews</i> , 2012, 11, 577-580.	5.8	38

#	ARTICLE	IF	CITATIONS
91	Glucocorticoid use and factors associated with variability in this use in the Systemic Lupus International Collaborating Clinics Inception Cohort. <i>Rheumatology</i> , 2018, 57, 677-687.	1.9	37
92	European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) SLE classification criteria item performance. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 775-781.	0.9	37
93	Sustained response to rituximab of autoimmune hemolytic anemia associated with antiphospholipid syndrome. <i>Haematologica</i> , 2004, 89, ECR34.	3.5	37
94	Reversible bone marrow depression by high-dose piperacillin/tazobactam. <i>British Journal of Haematology</i> , 1996, 95, 611-612.	2.5	36
95	Managing lupus patients during pregnancy. <i>Best Practice and Research in Clinical Rheumatology</i> , 2009, 23, 575-582.	3.3	36
96	Intensity and Duration of Anticoagulation Therapy in Antiphospholipid Syndrome. <i>Seminars in Thrombosis and Hemostasis</i> , 2012, 38, 339-347.	2.7	35
97	Peripheral Arterial Disease in Systemic Lupus Erythematosus: Prevalence and Risk Factors. <i>Journal of Rheumatology</i> , 2014, 41, 310-317.	2.0	35
98	Performance of the 2019 EULAR/ACR classification criteria for systemic lupus erythematosus in early disease, across sexes and ethnicities. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1333-1339.	0.9	35
99	Lupus pregnancy: is heparin a risk factor for osteoporosis?. <i>Lupus</i> , 2001, 10, 597-600.	1.6	34
100	Construction of a Frailty Index as a Novel Health Measure in Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , 2020, 47, 72-81.	2.0	34
101	Effectiveness of Nonpharmacologic Interventions for Decreasing Fatigue in Adults With Systemic Lupus Erythematosus: A Systematic Review. <i>Arthritis Care and Research</i> , 2016, 68, 141-148.	3.4	33
102	Cardiac valve replacement in patients with antiphospholipid syndrome. <i>Arthritis Care and Research</i> , 2012, 64, n/a-n/a.	3.4	32
103	Infections in newly diagnosed Spanish patients with systemic lupus erythematosus: data from the RELES cohort. <i>Lupus</i> , 2018, 27, 2253-2261.	1.6	32
104	Prolonged remission in SLE is possible by using reduced doses of prednisone: An observational study from the Lupus-Cruces and Lupus-Bordeaux inception cohorts. <i>Autoimmunity Reviews</i> , 2019, 18, 102359.	5.8	32
105	Update on therapy with thalidomide in the treatment of lupus. <i>Lupus</i> , 2001, 10, 188-192.	1.6	31
106	Hydroxychloroquine shortages among patients with systemic lupus erythematosus during the COVID-19 pandemic: experience of the Systemic Lupus International Collaborating Clinics. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1.1-2.	0.9	31
107	Impact of glucocorticoids on the incidence of lupus-related major organ damage: a systematic literature review and meta-regression analysis of longitudinal observational studies. <i>Lupus Science and Medicine</i> , 2021, 8, e000590.	2.7	31
108	Antiphospholipid Syndrome in Pregnancy. <i>Rheumatic Disease Clinics of North America</i> , 2007, 33, 287-297.	1.9	30

#	ARTICLE	IF	CITATIONS
109	A Prospective International Study on Adherence to Treatment in 305 Patients With Flaring <scp>SLE</scp>: Assessment by Drug Levels and Self-Administered Questionnaires. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 106, 374-382.	4.7	30
110	Treatment of systemic lupus erythematosus. <i>International Immunopharmacology</i> , 2001, 1, 1065-1075.	3.8	29
111	Heparin and osteoporosis during pregnancy: 2002 update. <i>Lupus</i> , 2002, 11, 680-682.	1.6	28
112	Soluble urokinase plasminogen activator receptor (suPAR) levels predict damage accrual in patients with recent-onset systemic lupus erythematosus. <i>Journal of Autoimmunity</i> , 2020, 106, 102340.	6.5	27
113	Seventy years after Henchâ€™s Nobel prize: revisiting the use of glucocorticoids in systemic lupus erythematosus. <i>Lupus</i> , 2020, 29, 1155-1167.	1.6	27
114	Hughes syndrome crosses boundaries. <i>Autoimmunity Reviews</i> , 2002, 1, 43-48.	5.8	26
115	Treatment of pregnancy loss in Hughes syndrome: a critical update. <i>Autoimmunity Reviews</i> , 2002, 1, 298-304.	5.8	26
116	Stroke and antiphospholipid syndrome: the treatment debate. <i>Rheumatology</i> , 2005, 44, 971-974.	1.9	26
117	Study of Flare Assessment in Systemic Lupus Erythematosus Based on Paper Patients. <i>Arthritis Care and Research</i> , 2018, 70, 98-103.	3.4	26
118	Prediction of Damage Accrual in Systemic Lupus Erythematosus Using the Systemic Lupus International Collaborating Clinics Frailty Index. <i>Arthritis and Rheumatology</i> , 2020, 72, 658-666.	5.6	26
119	Evaluating the Properties of a Frailty Index and Its Association With Mortality Risk Among Patients With Systemic Lupus Erythematosus. <i>Arthritis and Rheumatology</i> , 2019, 71, 1297-1307.	5.6	25
120	Breast Cancer in Systemic Lupus Erythematosus. <i>Oncology</i> , 2013, 85, 117-121.	1.9	24
121	Prevalence and predictors of valvular heart disease in patients with systemic lupus erythematosus. <i>Autoimmunity Reviews</i> , 2016, 15, 1134-1140.	5.8	24
122	Combined mepacrineâ€™hydroxychloroquine treatment in patients with systemic lupus erythematosus and refractory cutaneous and articular activity. <i>Lupus</i> , 2018, 27, 1718-1722.	1.6	24
123	LDLR and PCSK9 Are Associated with the Presence of Antiphospholipid Antibodies and the Development of Thrombosis in aPLA Carriers. <i>PLoS ONE</i> , 2016, 11, e0146990.	2.5	24
124	Diagnosis and treatment of lupus nephritis. Consensus document from the systemic auto-immune disease group (GEAS) of the Spanish Society of Internal Medicine (SEMI) and Spanish Society of Nephrology (S.E.N.). <i>Nefrologia</i> , 2012, 32 Suppl 1, 1-35.	0.4	24
125	Economic Evaluation of Damage Accrual in an International Systemic Lupus Erythematosus Inception Cohort Using a Multistate Model Approach. <i>Arthritis Care and Research</i> , 2020, 72, 1800-1808.	3.4	23
126	Does SLE flare during pregnancy?. <i>Scandinavian Journal of Rheumatology</i> , 1998, 27, 76-79.	1.1	22

#	ARTICLE	IF	CITATIONS
127	Septic Shock Due to <i>Pasteurella multocida</i> Subspecies <i>multocida</i> in a Previously Healthy Woman. <i>Clinical Infectious Diseases</i> , 1995, 21, 232-234.	5.8	21
128	Homocysteine, antiphospholipid antibodies and risk of thrombosis in patients with systemic lupus erythematosus. <i>Lupus</i> , 2004, 13, 927-933.	1.6	21
129	Breast cancer in systemic lupus. <i>Lupus</i> , 2017, 26, 311-315.	1.6	21
130	Economic Evaluation of Lupus Nephritis in the Systemic Lupus International Collaborating Clinics Inception Cohort Using a Multistate Model Approach. <i>Arthritis Care and Research</i> , 2018, 70, 1294-1302.	3.4	21
131	First month prednisone dose predicts prednisone burden during the following 11 months: an observational study from the RELES cohort. <i>Lupus Science and Medicine</i> , 2016, 3, e000153.	2.7	20
132	Cognitive Impairment in Patients With Neuropsychiatric and Non-neuropsychiatric Systemic Lupus Erythematosus: A Systematic Review and Meta-analysis. <i>Journal of the International Neuropsychological Society</i> , 2018, 24, 629-639.	1.8	20
133	Patient participation in a Clinical Guideline Development for Systemic Lupus Erythematosus. <i>Patient Education and Counseling</i> , 2015, 98, 1156-1163.	2.2	19
134	Evolution of retinal changes measured by optical coherence tomography in the assessment of hydroxychloroquine ocular safety in patients with systemic lupus erythematosus. <i>Lupus</i> , 2019, 28, 555-559.	1.6	19
135	Granulocyte Colony-Stimulating Factor for Neutropenia Secondary to Ticlopidine. <i>Acta Haematologica</i> , 1994, 91, 106-107.	1.4	18
136	Hepatotoxicity Associated with Penicillin V Therapy. <i>Clinical Infectious Diseases</i> , 1995, 20, 474-475.	5.8	18
137	Warfarin for multiple sclerosis?. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2000, 93, 497-499.	0.5	18
138	Therapy of systemic lupus erythematosus: new agents and new evidence. <i>Expert Opinion on Investigational Drugs</i> , 2000, 9, 1581-1593.	4.1	18
139	The treatment of antiphospholipid syndrome: A harmonic contrast. <i>Best Practice and Research in Clinical Rheumatology</i> , 2007, 21, 1079-1092.	3.3	18
140	Thrombotic Antiphospholipid Syndrome Shows Strong Haplotypic Association with SH2B3-ATXN2 Locus. <i>PLoS ONE</i> , 2013, 8, e67897.	2.5	18
141	Update on antimalarials and systemic lupus erythematosus. <i>Current Opinion in Rheumatology</i> , 2020, 32, 572-582.	4.3	18
142	Rituximab-refractory lupus nephritis successfully treated with belimumab. <i>Clinical and Experimental Rheumatology</i> , 2016, 34, 355-6.	0.8	18
143	Accrual of Atherosclerotic Vascular Events in a Multicenter Inception Systemic Lupus Erythematosus Cohort. <i>Arthritis and Rheumatology</i> , 2020, 72, 1734-1740.	5.6	17
144	EuroLupus cyclophosphamide plus repeated pulses of methyl-prednisolone for the induction therapy of class III, IV and V lupus nephritis. <i>Autoimmunity Reviews</i> , 2021, 20, 102898.	5.8	17

#	ARTICLE	IF	CITATIONS
145	Prosthetic-Valve Endocarditis Caused by Peptostreptococcus anaerobius. <i>Clinical Infectious Diseases</i> , 1995, 20, 1431-1431.	5.8	15
146	Osteopontin and Disease Activity in Patients with Recent-onset Systemic Lupus Erythematosus: Results from the SLICC Inception Cohort. <i>Journal of Rheumatology</i> , 2019, 46, 492-500.	2.0	15
147	Systemic lupus erythematosus and antiphospholipid syndrome during pregnancy: maternal and fetal complications and their management. <i>Israel Medical Association Journal</i> , 2000, 2, 462-9.	0.1	15
148	Systemic lupus erythematosus presenting as acute symptomatic hypercalcemia. <i>Lupus</i> , 2004, 13, 132-134.	1.6	14
149	Lower vitamin D is associated with metabolic syndrome and insulin resistance in systemic lupus: data from an international inception cohort. <i>Rheumatology</i> , 2021, 60, 4737-4747.	1.9	14
150	Cancer Risk in a Large Inception Systemic Lupus Erythematosus Cohort: Effects of Demographic Characteristics, Smoking, and Medications. <i>Arthritis Care and Research</i> , 2021, 73, 1789-1795.	3.4	13
151	Severe multiorgan flare of systemic lupus erythematosus successfully treated with rituximab and cyclophosphamide avoiding high doses of prednisone. <i>Lupus</i> , 2014, 23, 323-326.	1.6	12
152	Prevention of Recurrent Thrombosis in Antiphospholipid Syndrome: Different from the General Population?. <i>Current Rheumatology Reports</i> , 2016, 18, 26.	4.7	12
153	Tacrolimus in non-Asian patients with SLE: a real-life experience from three European centres. <i>Lupus Science and Medicine</i> , 2018, 5, e000274.	2.7	12
154	Low aspirin use and high prevalence of pre-eclampsia risk factors among pregnant women in a multinational SLE inception cohort. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1010-1012.	0.9	12
155	Trends in Hospital Admissions and Death Causes in Patients with Systemic Lupus Erythematosus: Spanish National Registry. <i>Journal of Clinical Medicine</i> , 2021, 10, 5749.	2.4	11
156	Polyarteritis Nodosa Presenting as Ischaemic Colitis. <i>Rheumatology</i> , 1996, 35, 1333-1334.	1.9	9
157	Prediction of hospitalizations in systemic lupus erythematosus using the Systemic Lupus International Collaborating Clinics Frailty Index (SLICC-FI). <i>Arthritis Care and Research</i> , 2020, , .	3.4	9
158	Longitudinal analysis of ANA in the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 1143-1150.	0.9	9
159	Neurosyphilis as a cause of dementia. Does it still exist?. <i>Journal of Infection</i> , 1995, 30, 186-187.	3.3	8
160	Aspirin to treat obstetric manifestations of the antiphospholipid syndrome. <i>American Journal of Obstetrics and Gynecology</i> , 2001, 185, 523-524.	1.3	8
161	SLE: the changing prognosis. <i>Lupus</i> , 2016, 25, 1285-1287.	1.6	8
162	Use of combined hormonal contraceptives among women with systemic lupus erythematosus with and without medical contraindications to oestrogen. <i>Rheumatology</i> , 2019, 58, 1259-1267.	1.9	8

#	ARTICLE	IF	CITATIONS
163	Clinical practice guidelines for systemic lupus erythematosus: Recommendations for general clinical management. <i>Medicina Clínica (English Edition)</i> , 2016, 146, 413.e1-413.e14.	0.2	7
164	Anti-phospholipid antibodies do not predict damage in SLE patients in the 21st century: an observational study from the Lupus-Cruces cohort. <i>Rheumatology</i> , 2021, 61, 249-257.	1.9	7
165	Neuropsychiatric Events in Systemic Lupus Erythematosus: Predictors of Occurrence and Resolution in a Longitudinal Analysis of an International Inception Cohort. <i>Arthritis and Rheumatology</i> , 2021, 73, 2293-2302.	5.6	7
166	Patterns of drug therapy in newly diagnosed Spanish patients with systemic lupus erythematosus. <i>Clinical and Experimental Rheumatology</i> , 2016, 34, 466-72.	0.8	7
167	Evaluating the Construct of Damage in Systemic Lupus Erythematosus. <i>Arthritis Care and Research</i> , 2023, 75, 998-1006.	3.4	7
168	Predictors of peripheral arterial disease in SLE change with patient's age. <i>Lupus Science and Medicine</i> , 2017, 4, e000190.	2.7	6
169	Pregnancy control in patients with systemic lupus erythematosus/antiphospholipid syndrome. Part 2: Pregnancy follow-up. <i>Reumatología Clínica (English Edition)</i> , 2021, 17, 125-131.	0.3	6
170	Prednisone in systemic lupus erythematosus: taper quickly, withdraw slowly. <i>Rheumatology</i> , 2021, 60, 5489-5490.	1.9	6
171	Prevention and Treatment of Thrombotic Antiphospholipid Syndrome. , 2017, , 223-233.		6
172	AB0542: Blocking the Human B Lymphocyte Stimulator Molecule (BLYS) Using A Monoclonal Antibody (Belimumab) in Systemic Lupus Erythematosus: First Results in Real-Life Spanish Patients with Refractory Disease (Biogears-Semi Registry). <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 985.2-985.	0.9	5
173	Características clínicas al diagnóstico de una cohorte prospectiva de pacientes con lupus eritematoso sistémico atendidos en servicios de Medicina Interna españoles: estudio RELES. <i>Revista Clínica Española</i> , 2017, 217, 7-14.	0.6	5
174	Control del embarazo en pacientes con lupus eritematoso sistémico/síndrome antifosfolípido. parte 2: seguimiento del embarazo. <i>Reumatología Clínica</i> , 2021, 17, 125-131.	0.5	5
175	Chronic Osteomyelitis Caused by <i>Salmonella</i> <i>fyris</i> . <i>Clinical Infectious Diseases</i> , 1994, 19, 221-221.	5.8	4
176	Treatment of the antiphospholipid syndrome in pregnancy. <i>Scandinavian Journal of Rheumatology</i> , 1998, 27, 44-47.	1.1	4
177	Gastroesophageal Reflux Disease. <i>New England Journal of Medicine</i> , 2009, 360, 729-730.	27.0	4
178	Antiphospholipid Antibodies and Risk for Recurrent Vascular Events. <i>JAMA - Journal of the American Medical Association</i> , 2004, 291, 2701.	7.4	4
179	Management of Thrombosis in Antiphospholipid Syndrome. , 2006, , 547-554.		4
180	Effectiveness and safety of medium-dose prednisone in giant cell arteritis: a retrospective cohort study of 103 patients. <i>Clinical and Experimental Rheumatology</i> , 2015, 33, S-90-7.	0.8	4

#	ARTICLE	IF	CITATIONS
181	Saving the kidneys in the lupus patient: Beyond immunosuppression, the need to collaborate across multiple disciplines. <i>European Journal of Internal Medicine</i> , 2022, 99, 19-21.	2.2	4
182	Control del embarazo en pacientes con lupus eritematoso sistémico y síndrome antifosfolípido. Parte 1: Infertilidad, preservación ovárica y valoración preconcepcional. Documento de consenso de la Sociedad Española de Ginecología y Obstetricia (SEGO), Sociedad Española de Medicina Interna (SEMI) y Sociedad Española de Reumatología (SER). <i>Reumatología Clínica</i> , 2021, 17, 61-66.	0.5	3
183	Control del embarazo en pacientes con lupus eritematoso sistémico/síndrome antifosfolípido. Parte 3. Parto. Puerperio. Lactancia. Anticoncepción. Recién nacido. <i>Reumatología Clínica</i> , 2021, 17, 183-186.	0.5	3
184	Pregnancy control in patients with systemic lupus erythematosus/antiphospholipid syndrome. Part 3: Childbirth. Puerperium. Breastfeeding contraception. Newborn. <i>Reumatología Clínica (English)</i> Tj ETQq0 0 0 rgBT /Oylock 10 Tf 50 6	0.5	3
185	Heart Disease, Pregnancy and Systemic Autoimmune Diseases. , 0, , 136-150.		3
186	Antiphospholipid syndrome: treatment controversies. <i>Future Rheumatology</i> , 2006, 1, 345-353.	0.2	3
187	Transplantation-mediated alloimmune thrombocytopenia successfully treated by retransplantation. <i>Lupus</i> , 2021, 30, 669-673.	1.6	3
188	Temporal Artery Biopsy and Corticosteroid Treatment: Changing Conclusions without Changing Evidence. <i>Annals of Internal Medicine</i> , 1997, 127, 248.	3.9	2
189	A new role for antimalarials in systemic lupus erythematosus treatment. <i>International Journal of Clinical Rheumatology</i> , 2010, 5, 299-312.	0.3	2
190	Cardiopulmonary Disease in SLE. , 2013, , 352-362.		2
191	Can we effectively treat lupus and reduce the side-effects of glucocorticoids?. <i>Lancet Rheumatology</i> , The, 2020, 2, e3-e5.	3.9	2
192	Homocisteína plasmática en pacientes con lupus eritematoso sistémico. <i>Medicina Clínica</i> , 2003, 120, 681-685.	0.6	2
193	Subacute Pneumococcal Endocarditis. <i>Clinical Infectious Diseases</i> , 1998, 27, 1341-1341.	5.8	1
194	Biologics use in sle in 23 centers â€“ data from the international registry for biologics in SLE. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, A9.1-A9.	0.9	1
195	Prevalence and Significance of Persistently Positive Antiphospholipid Antibodies in Women with Preeclampsia. <i>Journal of Rheumatology</i> , 2015, 42, 210-213.	2.0	1
196	Pregnancy in systemic autoimmune diseases: Myths, certainties and doubts. <i>Medicina Clínica (English)</i> Tj ETQq0 0 0 rgBT /Oylock 10 Tf 50 6	0.2	1
197	THU0304â€¦Adherence To Hydroxychloroquine as Assessed by Measurements of Drug and Metabolite Blood Levels in An International Prospective Study of Sle Patients in Flare. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 297.1-297.	0.9	1
198	Nitrated nucleosome levels and neuropsychiatric events in systemic lupus erythematosus; a multi-center retrospective case-control study. <i>Arthritis Research and Therapy</i> , 2017, 19, 287.	3.5	1

#	ARTICLE	IF	CITATIONS
199	Comment on: The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults. <i>Rheumatology</i> , 2018, 57, 1501-1502.	1.9	1
200	Hydroxychloroquine Retinal Toxicity and Its Association with Dosage. <i>Journal of Rheumatology</i> , 2021, 48, 150-150.	2.0	1
201	What are the topics you care about making trials in lupus more effective? Results of an Open Space meeting of international lupus experts. <i>Lupus Science and Medicine</i> , 2021, 8, e000506.	2.7	1
202	OPO289â€¦LLDAS (LOW LUPUS DISEASE ACTIVITY STATE), LOW DISEASE ACTIVITY (LDA) AND REMISSION (ON- OR) Tj ETQq0 0 0 rgBT MULTINATIONAL MULTICENTER COHORT. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 177-178.	0.9	1
203	Vitamin Supplementation and Risk of Stroke. <i>JAMA - Journal of the American Medical Association</i> , 2004, 291, 2191.	7.4	1
204	Task Force Report on the Management of Thrombosis in Antiphospholipid Syndrome. , 2012, , 167-179.		1
205	What are the prospects for antiplatelet agents for thromboprophylaxis in antiphospholipid syndrome?. <i>Expert Review of Clinical Immunology</i> , 2022, 18, 779-781.	3.0	1
206	Antiphospholipid Testing and Outcomeâ€™Reply. <i>Archives of Internal Medicine</i> , 2004, 164, 1701.	3.8	0
207	Comments on the Editorial â€™Antiphospholypid Syndrome: New Clinical and Therapeutic Perspectivesâ€™. <i>ReumatologÃa ClÃnica (English Edition)</i> , 2007, 3, 90.	0.3	0
208	Chapter 15 Treatment of Thrombosis in the Antiphospholipid Syndrome. <i>Handbook of Systemic Autoimmune Diseases</i> , 2009, , 185-191.	0.1	0
209	DiagnÃstico y tratamiento de la nefritis lÃpica: el camino del consenso. <i>Revista Clinica Espanola</i> , 2012, 212, 155-156.	0.6	0
210	Belimumab en el lupus eritematoso sistÃmico: una guÃa para su uso en la prÃctica diaria. <i>Revista Clinica Espanola</i> , 2013, 213, 66-67.	0.6	0
211	Gastroesophageal Reflux Disease. <i>Gastroenterology Research and Practice</i> , 2013, 2013, 1-2.	1.5	0
212	Managing Lupus Nephritis in Pregnant Women: Comment on the Article by Hahn et al. <i>Arthritis Care and Research</i> , 2013, 65, 1391-1392.	3.4	0
213	SAT0199â€¦An estimate of the proportion of patients with sle receiving off-label treatment with rituximab in european countries. <i>Annals of the Rheumatic Diseases</i> , 2013, 71, 539.1-539.	0.9	0
214	Dr. Erdozain, <i>et al</i> reply. <i>Journal of Rheumatology</i> , 2014, 41, 2086.2-2086.	2.0	0
215	Cancer risk factors in systemic lupus erythematosus: multivariate regression analysis in 16,409 patients. <i>Arthritis Research and Therapy</i> , 2014, 16, A35.	3.5	0
216	SAT0202â€¦International Multi-Centre Study to Evaluate the Clinical Significance of Phosphatidylserine-Dependent Antiprothrombin Antibodies for the Diagnosis of Antiphospholipid Syndrome. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 662.3-663.	0.9	0

#	ARTICLE	IF	CITATIONS
217	Treatment of Thrombosis in Antiphospholipid Syndrome. Handbook of Systemic Autoimmune Diseases, 2017, 12, 231-241.	0.1	0
218	Clinical characteristics during diagnosis of a prospective cohort of patients with systemic lupus erythematosus treated in Spanish Departments of Internal Medicine: The RELES study. Revista Clínica Española, 2017, 217, 7-14.	0.5	0
219	FRI0284â€¦Predictors of arterial vascular events in a cohort of systemic lupus erythematosus. , 2017, , .		0
220	OP0002â€¦Multicriteria decision analysis for developing new classification criteria for systemic lupus erythematosus. , 2017, , .		0
221	CS-07â€¦Economic evaluation of damage accrual in an international SLE inception cohort. , 2018, , .		0
222	OP0252â€¦NEUROPATHIES IN SYSTEMIC LUPUS ERYTHEMATOSUS: RESULTS FROM AN INTERNATIONAL, INCEPTION COHORT STUDY. , 2019, , .		0
223	P.368 Neuropsychiatric symptoms in patients with systemic lupus erythematosus: prevalence and its impact on quality of life. European Neuropsychopharmacology, 2020, 40, S211-S212.	0.7	0
224	Clinical presentation of antiphospholipid syndrome. , 2021, , 561-574.		0
225	Christmas Day in London: darling, I'm pregnant. BMJ: British Medical Journal, 2000, 321, 1539-1539.	2.3	0
226	THU0271â€¦PERFORMANCE OF THE EULAR/ACR 2019 CLASSIFICATION CRITERIA FOR SYSTEMIC LUPUS ERYTHEMATOSUS IN EARLY DISEASE, ACROSS SEXES AND ETHNICITIES. Annals of the Rheumatic Diseases, 2020, 79, 362.1-362.	0.9	0
227	FRI0152â€¦PULMONARY HYPERTENSION IN NEWLY DIAGNOSED SPANISH PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: DATA FROM THE RELES COHORT. Annals of the Rheumatic Diseases, 2020, 79, 660.2-660.	0.9	0
228	THU0256â€¦CARDIAC INVOLVEMENT IN NEWLY DIAGNOSED SPANISH PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: DATA FROM THE RELES COHORT. Annals of the Rheumatic Diseases, 2020, 79, 355.1-355.	0.9	0
229	1124â€¦Economic evaluation of neuropsychiatric (NP) lupus in an international inception cohort using a multistate model approach. , 2021, , .		0
230	1107â€¦Economic evaluation of hydroxychloroquine use in an international inception cohort. , 2021, , .		0
231	1704â€¦Identifying clusters of longitudinal autoantibody profiles associated with systemic lupus erythematosus disease outcomes. , 2021, , .		0
232	Interstitial Lung Disease Associated with Connective Tissue Disease (CTD-ILD): Retrospective Multicentric Study. , 2020, , .		0
233	Comparative study between two European inception cohorts of patients with early systemic lupus erythematosus. Clinical and Experimental Rheumatology, 2020, 38, 925-932.	0.8	0
234	Ankle-brachial index and arterial vascular events in systemic lupus erythematosus patients: a 5-year prospective cohort. Clinical and Experimental Rheumatology, 2020, 38, 978-984.	0.8	0

#	ARTICLE	IF	CITATIONS
235	P.0738 Mood and anxiety disorders in Systemic Lupus Erythematosus: results and insights from the Lupus-Cruces cohort. <i>European Neuropsychopharmacology</i> , 2021, 53, S538-S539.	0.7	0
236	Title is missing!. , 2020, 15, e0239401.		0
237	Title is missing!. , 2020, 15, e0239401.		0
238	Title is missing!. , 2020, 15, e0239401.		0
239	Title is missing!. , 2020, 15, e0239401.		0